Efficacy and Safety of Pafuramidine versus Pentamidine Maleate for Treatment of First Stage Sleeping Sickness in a Randomized, Comparator-Controlled, International Phase 3 Clinical Trial.

Autor: Gabriele Pohlig, Sonja C Bernhard, Johannes Blum, Christian Burri, Alain Mpanya, Jean-Pierre Fina Lubaki, Alfred Mpoo Mpoto, Blaise Fungula Munungu, Patrick Mangoni N'tombe, Gratias Kambau Manesa Deo, Pierre Nsele Mutantu, Florent Mbo Kuikumbi, Alain Fukinsia Mintwo, Augustin Kayeye Munungi, Amadeu Dala, Stephen Macharia, Constantin Miaka Mia Bilenge, Victor Kande Betu Ku Mesu, Jose Ramon Franco, Ndinga Dieyi Dituvanga, Richard R Tidwell, Carol A Olson

Publikováno v: PLoS Neglected Tropical Diseases, Vol 10, Iss 2, p e0004363 (2016)

BACKGROUND:Sleeping sickness (human African trypanosomiasis [HAT]) is a neglected tropical disease with limited treatment options that currently require parenteral administration. In previous studies, orally administered pafuramidine was well tolerat

Externí odkaz: https://doaj.org/article/54ad4e12d63a49d885737d44dd4774db

Trypanosomiasis Control, Democratic Republic of Congo, 1993–2003

Autor: Pascal Lutumba, Jo Robays, Constantin Miaka mia Bilenge, Victor Kande Betu Ku Mesu, Didier Molisho, Johan Declercq, Wim Van der Veken, Filip Meheus, Jean Jannin, Marleen Boelaert

Publikováno v: Emerging Infectious Diseases, Vol 11, Iss 9, Pp 1382-1388 (2005)

In the Democratic Republic of Congo (DRC), human African trypanosomiasis (HAT) reached unprecedented levels in the 1990s. To assess recent trends and evaluate control efforts, we analyzed epidemiologic and financial data collected by all agencies inv

Externí odkaz: https://doaj.org/article/2c0703f2cd2b44ca969bf0808c2c14a1

Averting a malaria disaster in Africa: where does the buck stop?

Autor: Christopher J.M. Whitty, Richard Allan, Virginia Wiseman, Sam Ochola, Maria Veronicah Nakyanzi-Mugisha, Benjamin Vonhm, Mahemba Mwita, Constantin Miaka, Aggrey Oloo, Zul Premji, Craig Burgess, Theonest K. Mutabingwa

Publikováno v: Bulletin of the World Health Organization, Vol 82, Iss 5, Pp 381-384

The serious threat posed by the spread of drug-resistant malaria in Africa has been widely acknowledged. Chloroquine resistance is now almost universal, and resistance to the successor drug, sulfadoxine-pyrimethamine (SP), is growing rapidly. Combina

Externí odkaz: https://doaj.org/article/cf353234996248d7a60fcab371a7ffbb

Effectiveness of a 10-Day Melarsoprol Schedule for the Treatment of Late-Stage Human African Trypanosomiasis: Confirmation from a Multinational Study (IMPAMEL II)

Autor: Impamel II Study, Schmid, Caecilia, Richer, Michaleen, Bilenge, Constantin Miaka Mia, Josenando, Théophile, Chappuis, Francois, Manthelot, Claude R., Nangouma, Auguste, Doua, Félix, Asumu, Pedro N., Simarro, Pere P., Burri, Christian

Publikováno v: The Journal of Infectious Diseases, 2005 Jun 01. 191(11), 1922-1931.

Externí odkaz: https://www.jstor.org/stable/30077845

Clinical study on the melarsoprol-related encephalopathic syndrome: risk factors and HLA association

Autor: Christian Burri, Gedeao Vatunga, Teófilo Josenando, Constantin Miaka Mia Bilenge, Jorge Luís Marques da Silva Atouguia, Pascal Lutumba, Jorge Seixas

Publikováno v: Tropical Medicine and Infectious Disease
Tropical Medicine and Infectious Disease; Volume 5; Issue 1; Pages: 5
Tropical Medicine and Infectious Disease, Vol 5, Iss 1, p 5 (2020)

Melarsoprol administration for the treatment of late-stage human African trypanosomiasis (HAT) is associated with the development of an unpredictable and badly characterized encephalopathic syndrome (ES), probably of immune origin, that kills approxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aff3de5ca95db2f8385a48f1b0c9cc52
https://edoc.unibas.ch/74213/